

**University of Maryland
Department of Radiation Oncology**

**Schedule of
Presentations and Activities**



**2021 Annual Meeting
Chicago, Illinois
October 24–27**

Saturday, October 23 Presentations

4:00 PM DIGITAL XP POSTER Q&A SESSION 01

Insurance approval for proton therapy in patients with thoracic malignancies: an experience from a cost-neutral payor environment

Mohindra P, Scull A, Molitoris JK, Mishra MV, Patel AN, Witek ME, Regine WF

Poster 2722

Systematic review and pooled analysis of the impact of treatment-induced lymphopenia on survival of glioblastoma patients

Saeed A, Bentzen SM, Mishra MV

Poster 3260

Sunday, October 24 Presentations

11:30 AM

Presidential Symposium: Session IV — Debate: Randomized Clinical Trials vs. Real World DataPro: Randomized controlled trials (RCT)

Bentzen S, presenter (pro)

Oral

Session PS 04, Rm W375

1:45 PM

Breast 1: Techniques and toxicities

Nichols EM, discussant

Session SS01, Rm W185

5:00 PM

Recent clinical results using GRID therapy boost

Regine WF

Oral

Joint session 01, Rm W186

1:30 PM POSTER Q&A SESSION 01 Outside Rm W375

SBRT for the treatment of isolated local recurrence of resected pancreatic cancer

Morris LK, Viehman JK, Baclay JRM, Chang DT, Kerans SJ, **Molitoris JK, Regine WF**, Johung K, Jethwa KR, Neibart SS, Jabbour SK, Hallemeier CL

Poster 2075

4:45 PM POSTER Q&A SESSION 02 Outside Rm W375

Using CBCT to monitor treatment dose delivery in head and neck proton radiotherapy

Sabouri P, Andersson S, Nilsson R, Eriksson K, **Mossahebi S**

Poster 2274

Keynote Addresses - ASTRO 2021

Monday, October 25, 9:45 AM [Keynote Address 01](#)

Wendy Dean, MD

Monday, October 25, 12:20 PM [Digital XP Keynote Address](#)

Fei-Fei Li, PhD

Monday, October 25 Presentations

2:25 PM

Dosimetric impact of dose rate fall-off in FLASH proton pencil beam scanning treatment

Bentfour EH, Sawant A, Mossahebi S

Oral

Session 62, Rm W184

2:50 PM

Analysis of radiation therapy quality assurance in NRG Oncology RTOG 0848

Tchelebi L, Winter K, Abrams RA, Safran H, **Regine WF**, McNulty S, Wu AJ, Du KL, Seaward SA, Bian SX, Aljumaily R, Shivnani AT, Moore T, Crocenzi T, DiPetrillo TA, Kuykendal A, Crane CH, Goodman KA

Oral

Session 76, Rm W375e

8:30 AM **POSTER Q&A SESSION 03** **Outside Rm W375**

Patterns of anesthesia use in a large multi-institution pediatric cohort: A report of the Pediatric Proton/Photon Consortium Registry (PPCR) Study

Blau MH, Indelicato DJ, Paulino AC, Hartsell WF, Laack NN II, Mangona VS, Wolden SL, Hill-Kayser CE, Perkins SM, **Kwok Y**, Perentesis JP, Chang J, MacEwan I, Eaton BR, Lavey RS, Yock TI, Ermoian RP

Poster 2322

Variability in proton craniospinal irradiation practices in the United States: A Pediatric Proton Consortium Registry (PPCR) Study

Connor M, Paulino AC, Ermoian RP, Hartsell WF, Indelicato DJ, Laack NN II, Wolden SL, Mangona VS, Perkins SM, Hill-Kayser CE, **Kwok Y**, Chang J, Lavey RS, Mladkova N, Yock TI, MacEwan I

Poster 2323

Novel radiation oncology physician productivity model

Nichols EM, Young F, Gerrity M, Vaughn M, Knight N, Regine WF

Poster 2346

1:30 PM **POSTER Q&A SESSION 05** **Outside Rm W375**

Updated toxicity and quality-of-life outcomes from a randomized phase III trial of extreme hypofractionated vs. standard fractionated proton therapy for low-risk prostate cancer

Bhangoo RS, DeWees TA, Thorpe CS, Petersen M, Hartsell WF, Chang J, Sinesi CC, **Mishra MV**, Mohammed N, McGee LA, Keole SR, Sweeney PJ, Gondi V, Vargas CE

Poster 2535

Rectal volume and quality of life in prostate cancer patients receiving *Pediococcus*-based probiotics and radiation therapy: A prospective randomized trial

Haskins C, Siddiqui O, Lin J, **Bentzen S, Mishra MV, Vujaskovic Z**

Poster 2559

Dosimetric parameters associated with pathologic response in patients undergoing preoperative spatially fractionated radiotherapy (GRID) for soft tissue sarcoma

Kunaprayoon D, Sun K, Mundis M, Mossahebi S, Houser T, Bentzen S, Vujaskovic Z, Regine WF

Poster 2643

Monday, October 25 Presentations (cont.)

Body composition and risk of all-cause mortality in men treated with radiation therapy for prostate cancer: A pooled analysis of NRG/RTOG 9406 and NRG/RTOG 0126

McDonald AM, DeMora L, Lenzie A, Hoyle J, Yang ES, Michalski JM, Parliament MB, Bahary JP, Hurwitz MD, Roach M III, Spratt DE, **Mishra MV**, Valicenti RK, Lau H, Souhami L, Mendez L, Chen Y, Doncals DE, Feng FY, Sandler HM

Poster 2576

Tuesday, October 26 Presentations

8:00 AM

Image guidance and motion management

Sawant A, moderator

Session SS14 Phys 5, Rm W185

1:50 PM

Accounting for serial and parallel functionality of the lung may minimize post-radiotherapy loss of respiratory function in lung cancer patients

Vicente EM, Modiri A, Kipritidis J, Hagan A, Yu KC, Yan Y, Owen DR, Matuszak M, **Mohindra P, Sun K**, Timmerman RD, **Sawant A**

Oral

Session 100, Rm W185

8:30 AM **POSTER Q&A SESSION 06** **Outside Rm W375**

Cardiac risk factors in black women with breast cancer undergoing proton therapy (PBT): Potential for increased therapeutic gain

Nichols EM, DeCesaris C, Paulosky K, **McAvoy SA, Ruff S, Vyfhuis MAL**

Poster 2669

From beaming cancer to beaming parent: Paternity leave experiences in radiation oncologist

Siddiqui O, Savla B, Chowdhary M, **McAvoy SA, Mishra MV**

Poster 2692

1:15 PM **POSTER Q&A SESSION 07** **Outside Rm W375**

Refining elective contralateral neck radiation volumes for oropharynx cancer

Witek ME, Woody NM, Musunuru HB, Hill PM, Yadav P, Burr A, Ko HC, Kimple RJ, Harari PM Jr

Poster 2836

Photobiomodulation laser therapy during chemoradiation for head and neck cancer: effect on mucositis, weight loss, and feeding tube dependence

Krc RF, Singh S, Weir JS

Poster 2763

3:30 PM **POSTER Q&A SESSION 08** **Outside Rm W375**

Role of modified frailty index in predicting oncologic outcomes from moderately hypofractionated radiotherapy for patients with Stage I-IIb non-small cell lung cancer

Cohen J, Sanchez-Cerro M, **Vyfhuis MAL**, Patel A, Dudley S, **Mohindra P**

Poster 2247

Lymphopenia assessment in stage III non-small-cell lung cancer (NSCLC) patients treated with proton or photon radiation therapy

Markan K, **Saeed A, Hamza MA, Vyfhuis MAL**, Scilla K, Mehra R, Rolfo C, **Mohindra P**

Poster 2926

Wednesday, October 27 Presentations

10:40 AM

High SMAD4 expression is associated with better clinical outcomes in patients with resectable pancreatic cancer: An analysis of NRG Oncology/RTOG 9704

Williams TM, Moughan J, Ben-Josef E, **Regine WF**, Timmers CD, Robb R, DiPetrillo TA, Leasure NC, Mowat E, Kim H, Koenig JM, Narayan S, Bush DA, Fromm M, Guha C

Session 1103, W178

10:45 AM

A prospective trial of aggressive therapy consisting of neoadjuvant chemotherapy and androgen deprivation followed by prostatectomy and adjuvant radiation in high-/very high-risk prostate cancer

Kwok Y, Mirkheshti N, Naslund M, Hussain A

Oral

Session 150, W183

10:40 AM

β -Catenin is independently associated with outcome in pancreatic cancer: An analysis of NRG Oncology/RTOG 9704

Ben-Josef E, Winter K, Williams TM, **Regine WF**, Timmers CD, Robb R, DiPetrillo TA, Leasure NC, Mowat R, Kim H, Koenig JM, Narayan S, Bush DA, Fromm M, Guha C

Session 1104, W178 Quick pitch

10:30 AM **POSTER Q&A SESSION 09** **Outside Rm W375**

Statistical approaches to optimize QACT frequency during proton therapy: An analysis of NRG Oncology/RTOG 9704

Biswal NC, Zakhary M, Mogilnay R, Nichols EM, Witek ME, Yi BY

Poster 3035

1:00 PM **POSTER Q&A SESSION 10** **Outside Rm W375**

PD-L1 expression level of primary tumor as a predictor of local control and symptomatic radiation necrosis in patients with brain metastases undergoing SRS/fSRT with concurrent immunotherapy

Alexander GS, Savla B, Berg LJ, Sun K, Remick JS, Kowalski ES, Chen S, Lamichhane N, **Regine WF**, Mishra MV

Poster 3183

Clinical outcomes of patients treated with intensity modulated proton therapy (IMPT) re-irradiation for gynecological malignancies

Pollock AE, Risher H, **Bentzen SM**, Roque DM, Rao G, Nichols EM, Mohindra P

Poster 3329

Preoperative radiosurgery for resected brain metastases: The PROPS-BM Multicenter Cohort Study

Prabhu RS, Dhakal R, Vaslow ZK, Dan T, **Mishra MV**, Patel T, Asher A, Yang K, Manning M, Stern JF, Patel AR, Wardak Z, Woodworth GF, Chao ST, Mohammed AM, Burr SH

Poster 3216

Incidence of symptomatic brain injury following pencil beam scanning proton beam therapy for management of central nervous system tumors

Savla B, Alexander G, Sun K, **Bentzen S**, Mossahebi S, Kwok Y, **Regine WF**, Mishra MV

Poster 3233

Wednesday, October 27 Presentations (cont.)

Optimal scheme in hypofractionated stereotactic radiation therapy for brain metastases

Siddiqui O, Haskins C, Bentzen SM, Mishra MV

Poster 3221

4:00 PM DIGITAL XP POSTER Q&A

Nodal clearance as a predictor of oncologic outcomes in esophageal and gastroesophageal junction malignancies receiving trimodality therapy

Berger M, DeCesaris C, Burrows W, Greenwald B, Tyer TN, Glass E, Mishra MV, Suntha M, Regine WF, Molitoris JK

Poster 2007

Phuoc Tran, MD, PhD, will be joining the department in December. His ASTRO presentations include:

Radiopharmaceutical Master Class: Radium-223 (prostate)

Tran PT

Master Class 01 Saturday, October 23, 2:05 PM Room W190 a/b

Quantification of tumor location and growth for orthotopic pancreatic cancer model using bioluminescence tomography-guided system

Deng Z, Xu X, Dehghani H, Reyes J, Wong JW, **Tran PT**, et al.

Poster 1001 Sunday, October 24, 1:50 PM Room W178 a/b

Emerging prognostic groups across the spectrum of metastatic castration-sensitive prostate cancer: disease outcomes and genomics

Sutera P, Van der Eecken K, Kishnan AU,....**Tran PT**, Deek, MP

Poster 2596 Monday, October 25, 1:30 PM Outside Rm W375

Individual patient level meta-analysis of prospective trials studying metastasis-directed therapy for metachronous oligometastatic prostate cancer

Tran PT, Berlin A, Siva A, et al.

Poster 2598 Monday, October 25, 1:30 PM Outside Rm W375

Identification and characterization of the molecular mechanisms of SCLC chemo-radiation resistance

Carrieri FAA, Connis N, Grasset E,....**Tran PT**.

Poster 2964 Tuesday, October 26, 3:30 PM Outside Rm W375

Prognostic significance of the risk of non-localized disease on PSMA/PET: Comparative performance of a novel, PSMA/PET-derived risk stratification tool for high-risk prostate cancer in a large, multi-institutional cohort

Ma TM, Xian M, Tilki D,**Tran PT**,....Kishan AU.

Oral 97 Tuesday, October 26, 8:55 AM Rm W181 a/b/c/

The relationship between androgen deprivation therapy duration and external beam radiotherapy with or without a brachytherapy boost in high-risk prostate cancer

Kishan AU, Wong JK, Merrick GS, **Tran PT**, et al.

Oral 148 Wednesday, October 27, 10:55 AM Room W183 a/b/c